Human IL-36 beta/IL-1F8 Biotinylated Antibody
R&D Systems, part of Bio-Techne | Catalog # BAF1099
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Met1-Glu157
Accession # Q3MIH0
Specificity
Clonality
Host
Isotype
Applications for Human IL-36 beta/IL-1F8 Biotinylated Antibody
Western Blot
Sample: Recombinant Human IL‑36 beta/IL‑1F8 (Catalog # 1099-IL)
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-36 beta/IL-1F8
Human interleukin 1 family member #8 [IL-1F8; also named Interleukin-36 beta, IL36B, FIL-1 eta (eta) and IL-1H2] is a member of the IL-1 family of proteins (1‑3). IL-1 family members include IL‑1 beta, IL-1 alpha, IL-1ra, IL-18 and IL-1F5 through F10 (4). All family members show a 12 beta-stranded beta-trefoil configuration, and are believed to have arisen from a common ancestral gene that has undergone multiple duplications (4). Two alternatively spliced transcript variants encode distinct (164 or 157 residues) protein isoforms that differ in their C-terminal 70 amino acid (aa) residues have been reported (3). IL-1F8 isoform 2 is synthesized as a 157 aa protein that contains no signal sequence and no prosegment (1, 2). Unlike IL-1F8 isoform 1 which lacks potential N‑linked glycosylation sites, isoform 2 contains one potential N-linked glycosylation site in its unique C-terminus. IL-1F8 is reported to be actively secreted (1). Human IL-1F8 isoform 2 shares 61% aa identity with mouse IL-1 ra, a 183 aa form of IL‑1F8. Within the IL-1 family, IL-1F8 shares 30%, 32%, 37%, 46%, 34%, 45% and 28% aa sequence identity with IL-1 ra, IL-1 beta, IL-1F5, F6, F7, F9 and F10, respectively. Cells reported to express IL-1F8 include resting and activated monocytes and B cells (1, 4). The receptor for IL-1F8 is reported to be a combination of IL-1 Rrp2 and IL-1 RAcP (5). Recombinant IL-1F8, along with IL-1F6 and IL-1F9, has been shown to activate the pathway involving NF-kappa B and MAPK in an IL-1 Rrp2 dependent manner.
References
- Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
- Kumar, S. et al. (2000) J. Biol. Chem. 275:10308.
- Nicklin, M.J.H. et al. (2002) Genomics 79:718.
- Dunn, E. et al. (2001) Trends Immunol. 22:533.
- Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional IL-36 beta/IL-1F8 Products
Product Documents for Human IL-36 beta/IL-1F8 Biotinylated Antibody
Product Specific Notices for Human IL-36 beta/IL-1F8 Biotinylated Antibody
For research use only